B-cell Lymphoma Clinical Trials in Philadelphia, Pennsylvania
16 recruitingPhiladelphia, Pennsylvania
Showing 1–16 of 16 trials
Recruiting
Phase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+12 more
National Cancer Institute (NCI)120 enrolled84 locationsNCT06649812
Recruiting
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mantle Cell LymphomaSmall Lymphocytic LymphomaB-cell Non Hodgkin Lymphoma+2 more
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Diffuse Large B Cell LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma+16 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 2
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Large B-cell Lymphoma
Allogene Therapeutics250 enrolled73 locationsNCT06500273
Recruiting
Early Phase 1
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Plasmablastic LymphomaAnn Arbor Stage I Diffuse Large B-Cell LymphomaAnn Arbor Stage II Diffuse Large B-Cell Lymphoma+2 more
AIDS Malignancy Consortium15 enrolled8 locationsNCT04139304
Recruiting
Phase 1Phase 2
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLarge B-cell Lymphoma+1 more
Lyell Immunopharma, Inc.270 enrolled34 locationsNCT05826535
Recruiting
Phase 2
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
High-grade B-cell LymphomaLymphoma, Non-HodgkinRefractory Diffuse Large B-Cell Lymphoma+2 more
Abramson Cancer Center at Penn Medicine31 enrolled1 locationNCT06458439
Recruiting
Phase 2
CAR-T Followed by Bispecific Antibodies
DLBCL - Diffuse Large B Cell LymphomaLarge B-cell Lymphoma
Abramson Cancer Center at Penn Medicine23 enrolled2 locationsNCT04889716
Recruiting
Phase 1
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
HIV InfectionRecurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+12 more
AIDS Malignancy Consortium20 enrolled6 locationsNCT05077527
Recruiting
Phase 1
SynKIR-310 for Relapsed/Refractory B-NHL
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma+23 more
Verismo Therapeutics36 enrolled5 locationsNCT06544265
Recruiting
Phase 2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
B-cell Non Hodgkin LymphomaFollicular Lymphoma ( FL)Large B-Cell Lymphoma (LBCL)
AstraZeneca240 enrolled94 locationsNCT06526793
Recruiting
Not Applicable
BHB & CAR-T for Lymphomas
Large B-cell Lymphoma
Abramson Cancer Center at Penn Medicine5 enrolled1 locationNCT06610344
Recruiting
Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma+4 more
SWOG Cancer Research Network396 enrolled87 locationsNCT05633615
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Non-Hodgkin LymphomaLymphomaLymphoma, Non-Hodgkin+4 more
Caribou Biosciences, Inc.72 enrolled38 locationsNCT04637763